Imagine you're a pharmaceutical giant with a war chest and a strategic plan. You look at the market and think, "We need to get into sleep medicine." Then you find a company with a promising pipeline of drugs that could help people stay awake during the day. What do you do? If you're Eli Lilly and Co. (LLY), you write a very large check.

That's essentially what happened Tuesday, as Lilly announced a definitive agreement to acquire Centessa Pharmaceuticals Plc (CNTA). The upfront price tag is about $6.3 billion in cash. But there's a potential bonus: another $1.5 billion in value tied to contingent value rights (CVRs), bringing the total potential deal value to around $7.8 billion. Investors loved the news, sending Centessa's stock soaring 45.16% to $40.03 in premarket trading—a new 52-week high.

So, what is Lilly buying for all that money? They're buying a key to the brain's sleep-wake switch. The crown jewel of the deal is Centessa's pipeline of orexin receptor 2 (OX2R) agonists. The lead candidate is a drug called cleminorexton, which has already posted promising results in Phase 2a clinical studies for various sleep disorders. In simple terms, these drugs aim to treat conditions like excessive daytime sleepiness by targeting a specific receptor pathway in the brain that regulates alertness.

For Lilly, this isn't just an acquisition; it's a strategic expansion of its neuroscience portfolio. The company is making a clear bet on the future of sleep medicine. The transaction is expected to close in the third quarter of this year, assuming it gets the thumbs-up from Centessa's shareholders and the usual regulatory bodies.

The deal comes at a time of leadership transition for Centessa. Back in December, the company appointed Mario Alberto Accardi—the President and founder of its Orexin Program—as its new CEO, effective January 1, 2026. He succeeded Saurabh Saha. Now, Accardi is poised to shepherd his company's flagship science into the hands of one of the world's largest pharmaceutical firms.

This acquisition is the latest move in what appears to be a shopping spree for Eli Lilly. The company has been on a deal-making tear in the biotech space. Just last month, in March, Lilly finalized a $2.75 billion agreement to bring AI-developed drugs from Hong Kong's Insilico Medicine to the global market—a partnership that began with a software licensing deal back in 2023.

Before that, in February, Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion. And the company had previously expressed interest in the French biotech Abivax SA (ABVX). Going back to January, Lilly also agreed to buy Ventyx Biosciences, Inc. for about $1.2 billion.

Put it all together, and you see a pattern: Eli Lilly is aggressively building out its therapeutic arsenal through strategic acquisitions. The Centessa deal, with its focus on neuroscience and sleep, is a multi-billion dollar bet that the science of staying awake is about to become a very big business. For now, Centessa shareholders are wide awake and celebrating.